ANZCTR search results

The purpose of this study is to test out a consumer engagement strategy called Making it Meaningful (MiM). The MiM has been designed for people who use cancer services and may be undergoing a change in their medications. Eligibility criteria: Outpatients who are receiving treatment or care at participating cancer service and aged 18 years or older will be eligible to take part. Patients who attend the service must identify their primary language as English or Mandarin to be eligible to participate Study details Participants who choose to enroll in this study will be randomly allocated to either receive the MiM medication management tool, or to receive standard care provided by the cancer service. Participants who are allocated to the MiM group will attend an appointment with their health practitioner (medical practitioner) who will use the Make it Meaningful Tool (MiM) to facilitate communication at the individual appointment where medications are changed. It is anticipated that this appointment will take no longer than your usual consultation. The health care practitioner will provide a paper copy of the MiM for the patient to take away from the appointment. The health care practitioner will also provide instructions to the patient about how the tool can be used to inform them of who to contact if they have any concerns about medication, treatment or experience side effects, etc.. Participants who are allocated to the standard care group will not receive the MiM tool, they will instead discuss the medication management together with their health care practitioner using the usual care strategy currently provided. All participants will be asked to complete a series of questionnaires over the phone when they first agree to participate in the study, 1 week and then 4 weeks after the medication discussion with their health care practitioner. It is expected that completion of these questionnaires will take 15 minutes. It is hoped this research will determine that use of the MiM tool is practical and acceptable to cancer patients. If this small study shows that the MiM tool is helpful for cancer patients, it may be studied further in a larger trial that may lead to improvements in medication communication for cancer patients in the future

This is a first-in-human, single-ascending and multiple-ascending dose study. Products with the same mode of action are approved in the form of intravenous infusions. The study drug was designed for local release in the colon. The purpose of the study is to assess the safety profile of this new drug in comparison to placebo.

This study is assessing the safety and efficacy of a new way of delivering radiotherapy, called Partially Ablative Body Radiotherapy (PABR), to tumours that are considered too bulky to treat with curative intent. Who is it for? You may be eligible for this study if you have a confirmed diagnosis of a non-haematologic malignancy not amenable to curative intent treatment, however are a candidate for palliative radiotherapy for a tumour size of at least 5cm. Study details Patients will undergo 5 sessions of radiotherapy on non-consecutive days over 2 weeks. The radiotherapy will be planned to deliver a higher dose to the core of the tumour and a lower, palliative dose to the periphery. Participants will have data collected on treatment related adverse events and tumour response to the radiotherapy, and will be asked to complete questionnaires on outcomes such as pain and quality of life. It is hoped that findings from this study will help develop PABR as a treatment modality for the palliation of bulky tumours.

In this study, we will assess the efficacy and safety of a dropless regimen in adequately controlling post-operative inflammation after cataract surgery. This study is a prospective, single-centre, non-randomized single-arm interventional study aiming to evaluate the tolerability of phacoemulsification without post-operative anti-inflammatory and antibiotics. This study will be conducted at the Royal Adelaide Hospital.

Patients with cardiac amyloidosis are known to have conduction disease, however, conduction disease is usually only identified once patients have developed overt heart failure. There is evidence to suggest that conduction disease may precede overt cardiac amyloidosis, providing an opportunity for earlier diagnosis and treatment of this condition.

This study aims to answer the question: Does use of a glucose telemetry system amongst hospitalised patients with diabetes mellitus treated with multiple daily injections of insulin improve glycaemic outcomes? Eligible participants will be randomised to the glucose telemetry system or to usual care. The glucose telemetry system will provide nursing staff with real-time glucose alerts to facilitate inpatient diabetes care. We will assess whether use of a glucose telemetry system improves inpatient glycaemia. We hypothesise that use of a glucose telemetry system in hospital will improve CGM-based glycaemic outcomes.

Within Gold Coast Health all patients who have their knee joint replaced (total knee arthroplasty) are referred for supervised outpatient physiotherapy after their surgery. This is in contrast to growing evidence that indicates that some patients who are having their knee joint replaced can achieve good post-surgery outcomes without the need for supervised outpatient physiotherapy, offering convenience and potential savings. The KAPPA criteria, previously established in a private sector cohort trial, demonstrated that simple and reproducible outcome measures assessed by a physiotherapist at two weeks post-surgery could determine which individuals could successfully continue with unsupervised rehabilitation versus those who would benefit from supervised outpatient physiotherapy. This project will validate these findings in a public health setting in patients who are undergoing knee joint replacement with the primary aim to compare the effectiveness and cost-efficiency of stratified physiotherapy using the KAPPA criteria with existing care through randomised methodology.

Physical activity (PA) is a promising intervention for children with ADHD that is safe, accessible, and effective in improving symptoms and mental skills. To maximise the effectiveness of PA programs for children with ADHD, researchers and clinicians need a better understanding of the brain mechanisms through which PA benefits children with ADHD. This information is essential for optimising treatment and will provide researchers with specific neurobiological targets for objectively evaluating PA interventions. The principal aim of this study is to examine the benefits of a tennis-based PA program on brain development, ADHD symptoms and mental skills in children with and without ADHD. It is hypothesized that PA will be associated with changes in brain development, ADHD symptoms and mental skills (executive functions). It is further hypothesised that PA induced brain changes will be associated with reduced ADHD symptoms and/or improved mental skills (executive functions) in children with and without ADHD.

A number of neurological disorders such as Parkinson’s disease (PD) are characterised by abnormal brain activity (e.g. unusually large numbers of neurons simultaneously active). Application of stimulation– in the form of mild electrical pulses or vibration – has been used as a therapeutic approach to reset the abnormal synchronous brain activity. ‘Peripheral stimulation’ involves the administration of non-invasive stimulation (mild electrical pulses or vibration) to patches of skin on the hands or feet. Early studies have shown that the use of a specific pattern of peripheral stimulation – called ‘coordinated reset stimulation’ – applied to the fingers, improved hand movements in patients with Parkinson’s disease, with benefits lasting several weeks. In this project, we aim to record the brain's response to ‘coordinated rest stimulation’ applied to the hands and feet in a group of healthy participants. This will assist in developing a future protocol for use with individuals with Parkinson’s Disease if indicated.

This study will investigate the safety and efficacy of low dose OIT (60mg of each nut protein) compared to standard dose multi-nut OIT (300mg of each nut protein) in children under 6 years old with one or more nut allergies. This study is a head-to-head, open label, randomised non-inferiority trial. A total of 208 children will be randomised 1:1 to low or standard dose multi-nut OIT, stratified by age and number of nut allergies. The primary outcome of this trial is sustained unresponsiveness to all nuts, defined as passing an oral food challenge to all nuts to which a participant was allergic at baseline, after completing 18 months of OIT followed by 4 weeks of nut avoidance. Secondary outcomes are desensitisation after 18 months of OIT (defined as passing an oral food challenge while still on uninterrupted OIT), safety, tolerability, feasibility, immune changes and patient-reported experience and outcomes of multi-nut OIT.